Please assess the completion status of the following clinical trial:

Trial Title: Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Histologically confirmed non-Hodgkin's lymphoma by brain biopsy~* Patients with inconclusive biopsy or patients who are not candidates for biopsy must have typical CT scan or MRI of the brain AND meet ≥ 1 of the following criteria:~  * Positive cerebrospinal fluid cytology for lymphoma OR a monoclonal lymphoid population as defined by cell surface markers or immunoglobulin gene rearrangement studies~ * Biopsy-proven involvement of the vitreous or uvea if cells are apparent in the posterior chamber or vitreous by ophthalmological examination~* Bideminsionally measurable disease, defined as contrast-enhancing tumor ≥ 1 cm by pretreatment MRI/CT scan~  * Meningeal or vitreous involvement constitutes evaluable but not measurable disease~ * If an excisional, rather than a needle biopsy was done, measurable disease must be present on a postoperative scan (not a PET-CT scan)~* ECOG performance status 0-3~* Absolute granulocyte count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Bilirubin ≤ upper limit of normal (ULN)~* SGOT ≤ 2.0 times ULN~* Creatinine clearance ≥ 50 mL/min~* Negative pregnancy test~* Fertile patients must use effective contraception~Exclusion criteria:~* Pregnant or nursing~* HIV-1 positivity~* Other malignancy within the past 5 years except basal cell skin cancer or any carcinoma in situ~* Pre-existing immunodeficiency~* Hepatitis B surface antigen positivity~* Systemic lymphoma (as determined by pre-registration CT scans and physical examination)~* Prior chemotherapy or radiotherapy for primary central nervous system lymphoma~* Prior organ or bone marrow transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab + standard chemotherapy (Type: EXPERIMENTAL): Rituximab + high dose methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine. Patients with meningeal involvement will receive additional methotrexate and leucovorin.

Based on this trial design, predict the completion outcome and termination type (if applicable).